top of page
Search

Skin Substitute Policy Updates Under OPPS: Where We Stand in 2027


Billing and reimbursement for skin substitutes/cellular or tissue-based products (CTPs) and their application codes underwent a significant change within CMS in 2026, specifically for hospitals paid under the Outpatient Perspective Payment System (OPPS).  As CMS continues to provide increased regulatory attention, this remains an area of focus going into 2027.  

Key Updates for 2027 for Sheet Form Products:

  • ALL sheet form products will be reimbursed the same rate of $127.14 per each cm2.  There will be no geographical adjustment for services provided in a hospital OPPS setting, so we all get the same reimbursement. 

  • Application codes for sheet form products will continue to be paid separately based upon anatomical location and size of total area(s) being treated (CPT codes 15271 – 15278)

  • The application codes for the 1st 25 cm2 are the primary procedure codes that carry reimbursement, (CPT codes 15271, 15273, 15275, and 15277).

  • The application add-on codes for each additional 25 cm2 are packaged into the primary procedure code, but still must be reported on the claim, (CPT codes 15272, 15274, 15276, and 15278).

  • Wastage continues to not be reimbursed, so product selection is of utmost importance.  Care should be taken to ensure the size product ordered and used aligns as closely as possible to the size of the wound(s) it is being applied to.

Key Updates for 2027 for Non-Sheet Form Products:

  • Effective April 1, 2026, CMS created new HCPCs Level II codes to represent the application of non-sheet form skin substitute/CTPs. Those codes are G0681-G0684 and in 2026 all had a status indicator of “N”, meaning they were packaged into payment for other services and not separately payable under OPPS.

  • Non-sheet form products are considered gels, powders, liquids, injectables, 3D printed constructs, etc.

  • In 2027, the primary application codes G0681 and G0683 have been given a status indicator of “T”, meaning they are a significant procedure with separate reimbursement under OPPS.  (Multiple procedure reductions may apply)

  • In 2027, the add-on application codes G0682 and G0684 continue to have a status indicator of “N” meaning they are packaged into the primary application code and not separately reimbursable under OPPS.

  • Because these products cannot be measured in the established manner as sheet form products are, they will also carry a status indicator of “N”, meaning they are not separately reimbursable.

Documentation and Medical Necessity

It is important to remember that whether a product or procedure is reimbursable, the service still needs to be accurately reflected in the documentation and on the claim submitted for payment.  Clinical documentation will likely continue to have increased scrutiny as payors seek evidence that the service provided met their medical necessity criteria.  Records should clearly describe wound characteristics, prior and current treatment, measurable progress, application details, and the plan for follow-up care.

Additionally, regardless of whether the product used is shelf stable or requires special storage requirements, if it falls within the classification of a tissue product as classified by CMS or The Joint Commission, etc., it should be entered into the tissue tracking log according to established standards and hospital policy.

Utilization and Coverage Requirements

Utilization limits, prior authorization requirements, coverage conditions, or requirements to demonstrate that conventional wound care has been attempted when clinically appropriate should be monitored during this treatment.  Requirements may vary by payer, special requirements specific to the patient’s insurer should be met prior to treatment.

Attention should also be paid to the acquisition costs of products compared to anticipated patient response to treatment and expected reimbursement.  If the product costs more than what the facility is likely going to get paid, has a high burden of co-pay for the patient, and the patient is not an appropriate candidate to have a favorable outcome from the procedure, it may not be the right choice to proceed with.

Conclusion

Skin substitute/CTP policy under OPPS in 2027 may affect reimbursement, documentation, product selection, and wound care operations.  Hospitals may need to revise product formularies, establish approval workflows, strengthen communication between clinical and revenue-cycle teams, and create escalation procedures for denied or underpaid claims. An authoritative review or audit can help identify policy impacts before they disrupt patient scheduling or product availability.    

 
 
 

Comments


Experienced · Responsive · Compliant · Cost Effective

© 2026 All Rights Reserved.

bottom of page